A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
A zero-inflated log-normal mixture model (which assumes that the data has a probability mass at zero and a continuous response for values greater than zero) with left censoring due to assay measurements falling below detection limits has been applied to compare treatment groups in randomized clinical trials and observational cohort studies. The sample size calculation (for a given type I error rate and a desired statistical power) has not been studied for this type of data under the assumption of equal proportions of true zeros in the treatment and control groups. In this article, we derive the sample sizes based on the expected differences between the non-zero values of individuals in treatment and control groups. Methods for calculation of statistical power are also presented. When computing the sample sizes, caution is needed as some irregularities occur, namely that the location parameter is sometimes underestimated due to the mixture distribution and left censoring. In such cases, the aforementioned methods fail. We calculated the required sample size for a recent randomized chemoprevention trial estimating the effect of oltipraz on reducing aflatoxin. A Monte Carlo simulation study was also conducted to investigate the performance of the proposed methods. The simulation results illustrate that the proposed methods provide adequate sample size estimates. However, when the aforementioned irregularity occurs, our methods are restricted and further research is needed.
Nie
Lei
L
Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, 4000 Reservoir Road, Washington, DC 20057, USA. ln54@georgetown.edu
Chu
Haitao
H
Cole
Stephen R
SR
D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D003198:Computer Simulation; D006801:Humans; D015233:Models, Statistical; D009010:Monte Carlo Method; D009369:Neoplasms / Q000517:prevention & control; D011719:Pyrazines / Q000627:therapeutic use; D018401:Sample Size; D013871:Thiones; D013876:Thiophenes
D016588:Anticarcinogenic Agents; D011719:Pyrazines; D013871:Thiones; D013876:Thiophenes; C026209:oltipraz